Participants in studies have recorded up to a 20% loss of body weight over a span of months
In both groups, distress is driven less by weight loss and more by a sudden change in appearance
Orforglipron is a once-daily, small-molecule GLP-1 receptor agonist that showed strong results in clinical trials, including 8% weight loss over 40 weeks
Az anyagi szempontok sem elhanyagolhatk A kezels kltsge sokak szmra jelenthet akadlyt
Primary care physicians will likely need education and training focused on this new class of medications, given a shortage of endocrinologists and obesity medicine specialists. Lee and colleagues noted there were study limitations, such as a lack of data on prescription indication, including whether it was used off-label. However, the increase in dispensing of injectable semaglutide for weight management suggests increasing use for this indication, they wrote
Acid reflux emerged as a reported concern in GLP-1 clinical trials, with roughly 2030% of semaglutide users describing heartburn or reflux symptoms in early weeks of treatment